This article was originally published in The Gray Sheet
The laser-based drug delivery technology developer closes a $19 million investment round, led by StemCell Holding AG. Announced July 20, the funding will support ongoing clinical trials of Pantec's P.L.E.A.S.E. (Painless Laser Epidermal System) technology for delivering in vitro fertilization hormone therapy. "This financing will allow us to move ahead with the clinical development of the [IVF] platform and visualize our goal of reaching market approval in Europe," said CEO Christof Boehler. Headquartered in Liechtenstein, privately held Pantec's technology uses a handheld laser to create "controlled aqueous micropores in the epidermis" for transdermal delivery of high molecular weight drugs, the company explains. Pantec values the IVF hormone therapy market at $1.5 billion to $2 billion
You may also be interested in...
Dispatches from a world turned upside down include FDA expressing confidence in Chinese manufacturers – to make their GDUFA payments; projections of drug shortages for ventilator patients; and the launch of new hydroxychloroquine studies.
A Phase III trial testing the antibody-drug conjugate sacituzumab govitecan was stopped early for efficacy, boding well for the BLA pending at the US FDA.
Deal Snapshot: Six companies seek to collect convalescent plasma from COVID-19 survivors to quickly develop hyperimmune immunoglobulin therapy for serious complications of the virus.